Ozgunes Ilhan, Erben Nurettin, Kiremitci Abdurahman, Kartal Elif D, Durmaz Gul, Colak Hasan, Usluer Gaye, Colak Ertugrul
Department of Clinical Microbiology and Infectious Diseases, Eskisehir, Turkey.
Saudi Med J. 2006 May;27(5):608-12.
To determine the prevalence of extended-spectrum beta-lactamase (ESBL) producing Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli), risk factors of ESBL-producing strains and antimicrobial susceptibility pattern of ESBL-producing and non producing strains.
The study took place at the Faculty of Medicine, Osmangazi University, Eskisehir, Turkey from March to November 2002. We evaluated 100 K. pneumoniae and 100 E. coli strains isolated from various clinical specimens, as well as the patients from whom these strains were isolated. The double-disk synergy test was performed on the isolates for the detection of ESBL. We visited the patients with a growth of E. coli or K. pneumoniae or both from their clinical specimens in their wards if they were hospitalized, while the outpatients with a growth of these microorganisms were evaluated from their hospital records.
The prevalence of ESBL-producing K. pneumoniae was 47% and E. coli was found as 12%. The ESBL-producing isolate rates were 50% (14/28) in intensive care units, 36.1% (35/97) in wards and 13.3% (10/75) in outpatients. Foley catheter (p<0.001), intravenous catheter (p<0.001), central venous catheter (p=0.002), intubation (p<0.001), surgery (p<0.001) and mechanical ventilation (p=0.002) were found as the risk factors for the acquisition of E. coli and K. pneumoniae with ESBLs.
In our study, the prevalence of ESBL-producing isolates was high. The results of the study suggest that an antimicrobial policy and early removal of interventional apparatus be of importance for the control of ESBL-producing K. pneumoniae and E. coli.
确定产超广谱β-内酰胺酶(ESBL)的肺炎克雷伯菌和大肠埃希菌的流行率、产ESBL菌株的危险因素以及产ESBL菌株和非产ESBL菌株的抗菌药敏模式。
该研究于2002年3月至11月在土耳其埃斯基谢希尔奥斯曼加齐大学医学院进行。我们评估了从各种临床标本中分离出的100株肺炎克雷伯菌和100株大肠埃希菌,以及分离出这些菌株的患者。对分离株进行双纸片协同试验以检测ESBL。如果患者住院,我们会到病房看望临床标本中培养出大肠埃希菌或肺炎克雷伯菌或两者皆有的患者,而对门诊中培养出这些微生物的患者则通过医院记录进行评估。
产ESBL的肺炎克雷伯菌流行率为47%,大肠埃希菌为12%。产ESBL分离株的发生率在重症监护病房为50%(14/28),病房为36.1%(35/97),门诊为13.3%(10/75)。导尿管(p<0.001)、静脉导管(p<0.001)、中心静脉导管(p=0.002)、插管(p<0.001)、手术(p<0.001)和机械通气(p=0.002)被发现是获得产ESBL大肠埃希菌和肺炎克雷伯菌的危险因素。
在我们的研究中,产ESBL分离株的流行率很高。研究结果表明,抗菌策略和早期移除介入器械对于控制产ESBL的肺炎克雷伯菌和大肠埃希菌很重要。